Previous 10 | Next 10 |
2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...
DUBLIN / ACCESSWIRE / April 21, 2023 / Alkermes plc (Nasdaq: ALKS ) recently announced that the company will accept applications for its Alkermes Inspiration Grants ® program beginning on May 1, 2023. Now in its seventh year, this competitive grant program will provide up to a total of...
NORTHAMPTON, MA / ACCESSWIRE / April 20, 2023 / Alkermes Alcohol Use Disorder (AUD) does not discriminate. But some communities are disproportionately affected. As we recognize both National Minority Health Month and Alcohol Awareness Month, we want to reiterate our commitment to all those li...
Alkermes to Report First Quarter Financial Results on April 26, 2023 PR Newswire DUBLIN , April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday,...
Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer PR Newswire – Application Period to Begin on May 1, 2023 – ...
Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business PR Newswire DUBLIN , April 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a confidential dra...
NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Alkermes (NASDAQ:ALKS) As part of last month's observance of Equal Pay Day , Alkermes reaffirms our commitment to closing long-standing pay gaps between men and women. We are proud of our efforts to date to minimize gender pay disparities, but k...
2023-03-29 06:38:25 ET Summary Alkermes' recent clinical trial results for Lybalvi demonstrate a promising treatment option for young adults with schizophrenia or bipolar I disorder who are early in the progression of their illness. The combination of olanzapine and samidorphan in...
NORTHAMPTON, MA / ACCESSWIRE / March 23, 2023 / Alkermes was recently named to Ragan Communications and PR Daily ' list of Top Places to Work for 2023! If you are interested in joining Team Alkermes, check out our careers page: https://bit.ly/3J6TBA0 View additional multimedia and more E...
Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness PR Newswire DUBLIN , March 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today annou...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...